The content on this site is intended for healthcare professionals only
Dr Marta Casarrubios speaks to ecancer in an online interview as part of the ELCC 2022 meeting about immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Dr Casarrubios explains about the methods they used and which gene signatures they looked at, before going into detail about their findings.
She concludes by talking about what can be taken away from these results and their potential for clinical impact.
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
